APOBEC2

Across TCGA pan-cancer cohorts, APOBEC2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of APOBEC2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where APOBEC2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types APOBEC2 is over-expressed in tumor, although a few such as PDAC and LSCC show the opposite, repressed pattern.

PDAC, LSCC, and HNSC are the cancer types where APOBEC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in APOBEC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−2.222	<.001	9	view →
LSCC	Female	All	−1.836	<.001	8	view →
HNSC	Male	All	−1.541	<.001	8	view →
LUAD	Female	II,III,IV	−1.495	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

APOBEC2–PDAC

Open the PDAC breakdown →